Catalio Capital Management LP Cuts Position in Supernus Pharmaceuticals, Inc. $SUPN

Catalio Capital Management LP cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 257,465 shares of the specialty pharmaceutical company’s stock after selling 29,625 shares during the quarter. Supernus Pharmaceuticals comprises about 2.4% of Catalio Capital Management LP’s portfolio, making the stock its 18th biggest position. Catalio Capital Management LP’s holdings in Supernus Pharmaceuticals were worth $12,796,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth about $51,000. Smartleaf Asset Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter worth about $55,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $43.58 on Thursday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -85.45, a PEG ratio of 0.93 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a twelve month low of $30.83 and a twelve month high of $59.68. The stock has a 50-day moving average of $48.27 and a 200 day moving average of $49.51.

Analysts Set New Price Targets

SUPN has been the topic of a number of recent research reports. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.